C4 Therapeutics, Inc.

Ryan E Michael

Yanke Liang

Christopher G Nasveschuk

Andrew John Phillips

James A Henderson

Kiel Lazarski

Georg Jaeschke

Antonio Ricci

Daniel Rueher

Martin Duplessis

Minsheng He

Annick Goergler

Mark E Fitzgerald

Chris G Nasveschuk

Alexander W Hird

Jae Young Ahn

The invention provides compounds that degrade the epidermal growth factor receptor (EGFR) including mutant forms via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.

Isoindolinone and indazole compounds for the degradation of EGFR

This invention provides heterocyclic compounds that bind to E3 Ubiquitin Ligase (typically through cereblon) ('Degrons'), which can be used as is or linked to a Targeting Ligand for a selected Target Protein for therapeutic purposes and methods of use and compositions thereof as well as methods for their preparation.

Heterocyclic degronimers for target protein degradation

This invention provides compounds that have spirocyclic E3 Ubiquitin Ligase targeting moieties (Degrons), which can be used as is or linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.

Spirocyclic degronimers for target protein degradation

Growing community of inventors

Newton, MA, United States of America

Ryan E Michael